Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 190

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Effect of Ibandronate on Bone Loss and Renal Function after Kidney Transplantation

GROTZ, WOLFGANG, NAGEL, CHRISTIAN, POESCHEL, DARIA, CYBULLA, MARKUS, PETERSEN, KARL-GEORG, UHL, MARKUS, STREY, CHRISTOPH, KIRSTE, GU[Combining Diaeresis]NTER, OLSCHEWSKI, MANFRED, REICHELT, ACHIM, RUMP, LARS CHRISTIAN · 2001 · Journal of the American Society of Nephrology

Abstract

: Severe osteoporosis frequently is observed after organ transplantation. In kidney transplantation, it adds to pre-existing renal bone disease and strategies to prevent osteoporosis are not established. Eighty kidney recipients were included in a randomized controlled prospective intervention trial. Treated patients (n = 40) received an injection of ibandronate, a bisphosphonate, immediately before and at 3, 6, and 9 mo after transplantation. The primary outcome measured was the change in bone mineral density. Secondary measures included graft outcome, spinal deformities, fracture rate, body height, and hormonal and metabolic data. Loss of spongy and cortical bone after transplantation was prevented by ibandronate. Changes of bone mineral density (ibandronate versus controls) were as follows: lumbar spine, -0.9 ± 6.1% versus -6.5 ± 5.4% (P < 0.0001); femoral neck, +0.5 ± 5.2% versus -7.7 ± 6.5% (P < 0.0001); and midfemoral shaft, +2.7 ± 12.2% versus -4.0 ± 10.9% (P = 0.024). Fewer spinal deformities developed with ibandronate (7 patients with 7 deformities versus 12 patients with 23 deformities; P = 0.047). Loss of body height was 0.5 ± 1.0 cm versus 1.1 ± 1.0 cm in control subjects (P = 0.040). Two bone fractures occurred in each group. There were fewer acute rejection episodes with ibandronate (11 versus 22; P = 0.009). Graft function after 1 yr was comparable. Bone loss, spinal deformation, and loss of body height during the first year after kidney transplantation are prevented by injection of ibandronate at intervals of 3 mo. The smaller number of rejection episodes of the ibandronate-treated group should be confirmed and its mechanism should be explored in additional studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.v1271530

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 190

Metadata

Authors
GROTZ, W., NAGEL, C., POESCHEL, D., CYBULLA, M., PETERSEN, K.-G., UHL, M., STREY, C., KIRSTE, G. D., OLSCHEWSKI, M., REICHELT, A., & RUMP, L. C.
Venue
Journal of the American Society of Nephrology
Published
2001-07
Volume
12
Issue
7
Pages
1530-1537
ISSN
1046-6673 (ISSN-L)
OpenAlex
W1900105093
Cited by
190
References
2
FWCI
9.21
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Ibandronate on Bone Loss and Renal Function after Kidney Transplantation. https://app.cochat.ai/papers/10.1681/asn.v1271530
The paper
GROTZ, W., NAGEL, C., POESCHEL, D., CYBULLA, M., PETERSEN, K.-G., UHL, M., STREY, C., KIRSTE, G. D., OLSCHEWSKI, M., REICHELT, A., & RUMP, L. C. (2001). Effect of Ibandronate on Bone Loss and Renal Function after Kidney Transplantation. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.v1271530

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.